Dr Martin Spitaler

Publications


Journals

  • Cebecauer M; Spitaler M; Sergé A; Magee AI. (1 Feb 2010). Signalling complexes and clusters: functional advantages and methodological hurdles. J Cell Sci. 123:309-320. DOI.
  • Engl C; Jovanovic G; Lloyd LJ; Murray H; Spitaler M; Ying L; Errington J; Buck M. (Aug 2009). In vivo localizations of membrane stress controllers PspA and PspG in Escherichia coli. Mol Microbiol. 73:382-396. DOI.
  • Ludescher C; Spitaler M; Hofmann J; Eisterer W; Hilbe W; Thaler J. (1 Nov 1995). MRP-, MDR1 expression and Rhodamine-123 efflux in B-CELL chronic lymphocytic leukemia. EUROPEAN JOURNAL OF CANCER. 31A:129-129. Author weblink.
  • Grunicke H; Kampfer S; Spitaler M; Hofmann J; Baier G; Uberall F. (1 Jun 1997). Antisense and dominant negative constructs as selective inhibitors of PKC isozymes. EUROPEAN JOURNAL OF CANCER. 33:117-117. Author weblink.
  • Hofmann J; Wolf A; Spitaler M; Böck G; Drach J; Ludescher C; Grunicke H. (1992). Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol. 118:361-366.
  • Ludescher C; Thaler J; Drach D; Drach J; Spitaler M; Gattringer C; Huber H; Hofmann J. (Sep 1992). Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol. 82:161-168.
  • Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J. (Jan 1996). Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Anticancer Res. 16:289-296.
  • Hofmann J; Utz I; Spitaler M; Hofer S; Rybczynska M; Beck WT; Herrmann DB; Grunicke H. (1997). Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440). Br J Cancer. 76:862-869.
  • Pall G; Spitaler M; Hofmann J; Thaler J; Ludescher C. (Jul 1997). Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia. 11:1067-1072.
  • Utz I; Spitaler M; Rybczynska M; Ludescher C; Hilbe W; Regenass U; Grunicke H; Hofmann J. (3 Jul 1998). Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int J Cancer. 77:64-69.
  • Spitaler M; Utz I; Hilbe W; Hofmann J; Grunicke HH. (1 Oct 1998). PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem Pharmacol. 56:861-869.
  • Uberall F; Hellbert K; Kampfer S; Maly K; Villunger A; Spitaler M; Mwanjewe J; Baier-Bitterlich G; et alBaier G; Grunicke HH. (8 Feb 1999). Evidence that atypical protein kinase C-lambda and atypical protein kinase C-zeta participate in Ras-mediated reorganization of the F-actin cytoskeleton. J Cell Biol. 144:413-425.
  • Spitaler M; Wiesenhofer B; Biedermann V; Seppi T; Zimmermann J; Grunicke H; Hofmann J. (Sep 1999). The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res. 19:3969-3976.
  • Spitaler M; Villunger A; Grunicke H; Uberall F. (27 Oct 2000). Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota. J Biol Chem. 275:33289-33296. DOI.
  • Rybczynska M; Liu R; Lu P; Sharom FJ; Steinfels E; Pietro AD; Spitaler M; Grunicke H; et alHofmann J. (18 May 2001). MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer. 84:1405-1411. DOI.
  • Grunicke HH; Kampfer S; Spitaler M; Hochholdinger F; Baier G; Uberall F. (2001). Elements of signal transduction in drug discovery with special reference to inhibitors of protein kinase C. Ernst Schering Res Found Workshop. 81-99.
  • Bauer B; Krumböck N; Fresser F; Hochholdinger F; Spitaler M; Simm A; Uberall F; Schraven B; et alBaier G. (24 Aug 2001). Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells. J Biol Chem. 276:31627-31634. DOI.
  • Rybczynska M; Spitaler M; Knebel NG; Boeck G; Grunicke H; Hofmann J. (15 Sep 2001). Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem Pharmacol. 62:765-772.
  • Mwanjewe J; Spitaler M; Ebner M; Windegger M; Geiger M; Kampfer S; Hofmann J; Uberall F; et alGrunicke HH. (1 Oct 2001). Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota. Biochem J. 359:211-217.
  • Grunicke HH; Spitaler M; Mwanjewe J; Schwaiger W; Jenny M; Ueberall F. (2003). Regulation of cell survival by atypical protein kinase C isozymes. Adv Enzyme Regul. 43:213-228.
  • Spitaler M; Cantrell DA. (Aug 2004). Protein kinase C and beyond. Nat Immunol. 5:785-790. DOI.
  • Matthews SA; Liu P; Spitaler M; Olson EN; McKinsey TA; Cantrell DA; Scharenberg AM. (Feb 2006). Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol Cell Biol. 26:1569-1577. DOI.
  • Spitaler M; Emslie E; Wood CD; Cantrell D. (May 2006). Diacylglycerol and protein kinase D localization during T lymphocyte activation. Immunity. 24:535-546. DOI.

Conferences

  • HOFMANN J; WOLF A; SPITALER M; UBERALL F; HERRMANN DBJ; GRUNICKE H. THE NEW ANTICANCER DRUG ILMOFOSINE ENHANCES THE ACTIVITY OF CISPLATIN AND REVERSES MULTIDRUG RESISTANCE. 2ND INTERNATIONAL CONF ON EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RADIATION INJURY, 17 Sep 1991 - 21 Sep 1991. 71:603-605. KLUWER ACADEMIC PUBLISHERS (1 Jan 1993). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook